MedPath

A clinical trial to study the effect of ayurvedic drug compound, Nimbashatak Vati in patient with intestinal worm infestation

Phase 1/2
Completed
Conditions
krimi(intestinal worm infestation)
Registration Number
CTRI/2017/11/010377
Lead Sponsor
Mahesh Patel
Brief Summary

This study is a randomized controlled clinical study to evaluate the efficacy of Nimbashatak vati (tablet prepared out of 6 anti-helminthic drugs mentioned in ayurvedic treaties- Yog-Ratnakar) and tab Albendazole in the management of krimi(intestinal worm infestation).The primary outcome measures are changes in subsidence of the clinical sign and symptoms measured at baseline and after 2 week in control group and  abscence of recurrence during follow up. Changes in stool report in baseline ,after 4 weeks of intervention, and for 2 times during follow up period will also be conducted to assess the efficacy of treatment to prevent the recurrence. Secondary outcome measures are changes in general health condition like body weight ,Agni bala, Deha bala, Chetas bala at Baseline and after 4 weeks.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
30
Inclusion Criteria

children with clinical feature of krimiroga and positive stool report for intestinal helminthic infestation (cyst and ova).

Exclusion Criteria

patient with major congenital disorders and chronic debilitating disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in subsidence of the clinical sign and symptoms with negative stool report for ova and cyst.28 days in both intervention and control grroup
Secondary Outcome Measures
NameTimeMethod
improvement in general health condition and quality of life.After 30 days

Trial Locations

Locations (1)

Parul Institute of Ayurvedal

🇮🇳

Vadodara, GUJARAT, India

Parul Institute of Ayurvedal
🇮🇳Vadodara, GUJARAT, India
Mahesh Patel
Principal investigator
9909597376
drmjp007@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.